ESG Report 2020

PRODUCT AND SERVICE QUALITY The success of a pharmaceutical manufacturer connection to the latest version of Chinese depends on the safety and effectiveness of its Pharmacopoeia, which came into effect at year- medicines, and the quality of medicines is end. The Group fully cooperates with the undoubtedly a top priority for The United enhancement of national requirements regarding Laboratories. The government also sets high the safety, effectiveness, technical application and quality standards on the pharmaceutical industry system of standards of medicines. The United and attaches great importance to the quality Laboratories treats the amendment of the management of pharmaceutical companies. To Pharmacopoeia as an opportunity and enhanced closely follow the development of national policies, its internal quality control procedures to improve the Group took the initiative during the Year by the Group's products and service quality. reviewing and improving its quality management in Zhuhai Company's Quality Management Optimisation Work on the Amendments of Chinese Pharmacopoeia T h e N a t i o n a l Me d i c a l P r o d u c t s technologies, conducting quality impact Administration ( “ NMPA ” ) has issued the assessment on the changes involving our 2020 Edition of the Chinese Pharmacopoeia products, as well as organising training and ( new Pharmacopoeia ) on July 2020, which learning sessions for employees to prepare came into force as of 30 December 2020. for the launch of all related optimisation The amendments of the Pharmacopoeia work. Since the promulgation of the new include expanding the use of advance and Pharmacopoeia, Zhuhai Company actively mature analytical technology, strengthening organised internal and external training for the requirements for the applicability of employees involved in production, quality, analytical methods, adding new and revised s a l e s , p ro c u reme nt , s to rage a nd the testing methods for certain substances transportation, including online training and increasing requirements regarding organised by the Chinese Pharmacopeia impurity control, while the implementation Commission, training on the revised work involves review on the Group ’ s quality standards of our products, analysing the standards, testing and recording methods differences between new and previous and introduction of testing instruments, Pharmacopoeia for insulin and training on reagents and consumables. the Pharmacopoeia and quality control for departments. Besides, Zhuhai company also To smoothly implement the amendments in organised cross-department meetings and the new Pharmacopoeia, Zhuhai Company k n ow l e d g e c o n t e s t o n t h e n e w planned the internal optimisation work at Pharmacopoeia, so as to enhance the the first place, which include comparing the understanding and application of the differences between the new and previous Pharmacopoeia among employees through edition of the Pharmacopoeia, researching various types of activities. on the new and revised relevant general “ ” 36 Environmental, Social and Governance Report 2020 The United Laboratories International Holdings Limited